Stay updated on AK002 for Eosinophilic Gastritis Clinical Trial
Sign up to get notified when there's something new on the AK002 for Eosinophilic Gastritis Clinical Trial page.

Latest updates to the AK002 for Eosinophilic Gastritis Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check16 days agoChange DetectedThe page has undergone significant content removal regarding a Phase 3 study of lirentelimab (AK002) for Eosinophilic Gastritis, including detailed inclusion and exclusion criteria, while a new revision number has been added.SummaryDifference27%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check67 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to AK002 for Eosinophilic Gastritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AK002 for Eosinophilic Gastritis Clinical Trial page.